Literature DB >> 23625211

Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II.

Joshua A Beckman1, Francesco Paneni, Francesco Cosentino, Mark A Creager.   

Abstract

In part II of this review, we describe the epidemiology and clinical consequences of vascular disease in patients with diabetes, and discuss the efficacy of risk factor modification and antiplatelet treatment. Specifically, evidence-based cardiovascular therapies are discussed through novel clinical insights on management of hyperglycaemia, hypertension, dyslipidaemia as well as platelet dysfunction. Recent trends in the incidence and outcomes of vascular disease in diabetes suggest that timely and effective implementation of therapies is making a favourable impact.

Entities:  

Keywords:  Diabetes; Medical therapy; Vascular disease

Mesh:

Substances:

Year:  2013        PMID: 23625211     DOI: 10.1093/eurheartj/eht142

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  98 in total

1.  Mechanisms-based therapeutic strategies in type 2 diabetes.

Authors:  Francesco Paneni; Sarah Costantino
Journal:  Cardiovasc Diagn Ther       Date:  2015-10

2.  Endocrine Regulator rFGF21 (Recombinant Human Fibroblast Growth Factor 21) Improves Neurological Outcomes Following Focal Ischemic Stroke of Type 2 Diabetes Mellitus Male Mice.

Authors:  Yinghua Jiang; Ning Liu; Qingzhi Wang; Zhanyang Yu; Li Lin; Jing Yuan; Shuzhen Guo; Bum Ju Ahn; Xiao-Jie Wang; Xiaokun Li; Eng H Lo; Xiaochuan Sun; Xiaoying Wang
Journal:  Stroke       Date:  2018-12       Impact factor: 7.914

Review 3.  Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk.

Authors:  Allison B Goldfine; Steven E Shoelson
Journal:  J Clin Invest       Date:  2017-01-03       Impact factor: 14.808

Review 4.  The perils of surrogate endpoints.

Authors:  William S Weintraub; Thomas F Lüscher; Stuart Pocock
Journal:  Eur Heart J       Date:  2015-05-13       Impact factor: 29.983

5.  Atazanavir improves cardiometabolic measures but not vascular function in patients with long-standing type 1 diabetes mellitus.

Authors:  Jessica Milian; Allison B Goldfine; Jonah P Zuflacht; Caitlin Parmer; Joshua A Beckman
Journal:  Acta Diabetol       Date:  2015-01-08       Impact factor: 4.280

6.  The use of an occlusion perfusion catheter to deliver paclitaxel to the arterial wall.

Authors:  Marzieh K Atigh; Emily Turner; Uwe Christians; Saami K Yazdani
Journal:  Cardiovasc Ther       Date:  2017-08       Impact factor: 3.023

7.  Inhibition of TLR4 attenuates vascular dysfunction and oxidative stress in diabetic rats.

Authors:  Maria Alicia Carrillo-Sepulveda; Kathryn Spitler; Deepesh Pandey; Dan E Berkowitz; Takayuki Matsumoto
Journal:  J Mol Med (Berl)       Date:  2015-07-17       Impact factor: 4.599

8.  Trends and Disparities in Cardiovascular Mortality Among U.S. Adults With and Without Self-Reported Diabetes, 1988-2015.

Authors:  Yiling J Cheng; Giuseppina Imperatore; Linda S Geiss; Sharon H Saydah; Ann L Albright; Mohammed K Ali; Edward W Gregg
Journal:  Diabetes Care       Date:  2018-08-21       Impact factor: 19.112

Review 9.  Global aetiology and epidemiology of type 2 diabetes mellitus and its complications.

Authors:  Yan Zheng; Sylvia H Ley; Frank B Hu
Journal:  Nat Rev Endocrinol       Date:  2017-12-08       Impact factor: 43.330

10.  Glucose induces sensitivity to oxygen deprivation and modulates insulin/IGF-1 signaling and lipid biosynthesis in Caenorhabditis elegans.

Authors:  Anastacia M Garcia; Mary L Ladage; Dennis R Dumesnil; Khadiza Zaman; Vladimir Shulaev; Rajeev K Azad; Pamela A Padilla
Journal:  Genetics       Date:  2015-03-10       Impact factor: 4.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.